aldesleukin

Overview

Aldesleukin (recombinant interleukin-2, IL-2) is a cytokine immunotherapy used in advanced melanoma and renal cell carcinoma. It promotes T-cell proliferation and activation. Prior aldesleukin response data in melanoma have been used to contextualize the immunological significance of tumor-infiltrating lymphocyte signatures in genomic studies.

Evidence in the corpus

• Prior aldesleukin/interferon-alpha response data in melanoma used to contextualize the Immune transcriptomic subclass survival advantage (51% of 329 TCGA cases) identified in TCGA melanoma integrative analysis; the authors draw parallels with existing immunotherapy data but caution that predictive value for checkpoint blockade is unproven PMID:26091043

Resistance mechanisms

Cancer types (linked)

Sources

This page was processed by entity-page-writer on 2026-05-14.